552 related articles for article (PubMed ID: 29907945)
21. A choice of radionuclide: Comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma.
Takiar V; Voong KR; Gombos DS; Mourtada F; Rechner LA; Lawyer AA; Morrison WH; Garden AS; Beadle BM
Pract Radiat Oncol; 2015; 5(3):e169-e176. PubMed ID: 25423888
[TBL] [Abstract][Full Text] [Related]
22. Proton Beam Irradiation: A Safe Procedure in Postequatorial Extraocular Extension From Uveal Melanoma.
Seibel I; Riechardt AI; Erb-Eigner K; Böker A; Cordini D; Heufelder J; Joussen AM
Am J Ophthalmol; 2018 Jul; 191():49-53. PubMed ID: 29655645
[TBL] [Abstract][Full Text] [Related]
23. Proton beam therapy for the treatment of uveal melanoma in Scotland.
Macdonald EC; Cauchi P; Kemp EG
Br J Ophthalmol; 2011 Dec; 95(12):1691-5. PubMed ID: 21216794
[TBL] [Abstract][Full Text] [Related]
24. Incidence and indications for pars plana vitrectomy following the treatment of posterior uveal melanomas in Scotland.
Chia SN; Smith HB; Hammer HM; Kemp EG
Eye (Lond); 2015 Jun; 29(6):748-56. PubMed ID: 25853443
[TBL] [Abstract][Full Text] [Related]
25. Predictive risk factors for radiation retinopathy and optic neuropathy after proton beam therapy for uveal melanoma.
Seibel I; Cordini D; Hager A; Tillner J; Riechardt AI; Heufelder J; Davids AM; Rehak M; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2016 Sep; 254(9):1787-92. PubMed ID: 27376824
[TBL] [Abstract][Full Text] [Related]
26. Local recurrence after uveal melanoma proton beam therapy: recurrence types and prognostic consequences.
Caujolle JP; Paoli V; Chamorey E; Maschi C; Baillif S; Herault J; Gastaud P; Hannoun-Levi JM
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1218-24. PubMed ID: 23177670
[TBL] [Abstract][Full Text] [Related]
27. [High-dose 106Ruthenium plaque brachytherapy for posterior uveal melanoma. A clinico-pathologic study].
Heindl LM; Lotter M; Strnad V; Sauer R; Naumann GO; Knorr HL
Ophthalmologe; 2007 Feb; 104(2):149-57. PubMed ID: 17123048
[TBL] [Abstract][Full Text] [Related]
28. Impact of dose rate on clinical course in uveal melanoma after brachytherapy with ruthenium-106.
Mossböck G; Rauscher T; Winkler P; Kapp KS; Langmann G
Strahlenther Onkol; 2007 Oct; 183(10):571-5. PubMed ID: 17896089
[TBL] [Abstract][Full Text] [Related]
29. Secondary Enucleations for Uveal Melanoma: A 7-Year Retrospective Analysis.
Fabian ID; Tomkins-Netzer O; Stoker I; Arora AK; Sagoo MS; Cohen VM
Am J Ophthalmol; 2015 Dec; 160(6):1104-1110.e1. PubMed ID: 26344583
[TBL] [Abstract][Full Text] [Related]
30. Proton therapy for uveal melanoma in 43 juvenile patients: long-term results.
Petrovic A; Bergin C; Schalenbourg A; Goitein G; Zografos L
Ophthalmology; 2014 Apr; 121(4):898-904. PubMed ID: 24405742
[TBL] [Abstract][Full Text] [Related]
31. Long-term Outcomes After Proton Beam Irradiation in Patients With Large Choroidal Melanomas.
Papakostas TD; Lane AM; Morrison M; Gragoudas ES; Kim IK
JAMA Ophthalmol; 2017 Nov; 135(11):1191-1196. PubMed ID: 29049518
[TBL] [Abstract][Full Text] [Related]
32. Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation.
Krohn J; Monge OR; Skorpen TN; Mørk SJ; Dahl O
Eye (Lond); 2008 Nov; 22(11):1398-403. PubMed ID: 17585309
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of treatment with stereotactic radiosurgery or proton beam therapy for choroidal melanoma.
Sikuade MJ; Salvi S; Rundle PA; Errington DG; Kacperek A; Rennie IG
Eye (Lond); 2015 Sep; 29(9):1194-8. PubMed ID: 26160531
[TBL] [Abstract][Full Text] [Related]
34. Retrospective evaluation of patients with uveal melanoma treated by stereotactic radiosurgery with and without tumor resection.
Suesskind D; Scheiderbauer J; Buchgeister M; Partsch M; Budach W; Bartz-Schmidt KU; Ritz R; Grisanti S; Paulsen F
JAMA Ophthalmol; 2013 May; 131(5):630-7. PubMed ID: 23494018
[TBL] [Abstract][Full Text] [Related]
35. Pigmented episcleral deposits after brachytherapy of uveal melanoma.
Toivonen P; Kivelä T
Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal bevacizumab for neovascular glaucoma in uveal melanoma treated by proton beam therapy.
Mahdjoubi A; Najean M; Lemaitre S; Dureau S; Dendale R; Levy C; Rouic LL; Desjardins L; Cassoux N
Graefes Arch Clin Exp Ophthalmol; 2018 Feb; 256(2):411-420. PubMed ID: 29116399
[TBL] [Abstract][Full Text] [Related]
37. Plaque brachytherapy for uveal melanoma: a vision prognostication model.
Khan N; Khan MK; Bena J; Macklis R; Singh AD
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e285-90. PubMed ID: 22658514
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
[TBL] [Abstract][Full Text] [Related]
39. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO).
Dendale R; Lumbroso-Le Rouic L; Noel G; Feuvret L; Levy C; Delacroix S; Meyer A; Nauraye C; Mazal A; Mammar H; Garcia P; D'Hermies F; Frau E; Plancher C; Asselain B; Schlienger P; Mazeron JJ; Desjardins L
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):780-7. PubMed ID: 16647221
[TBL] [Abstract][Full Text] [Related]
40. Proton beam radiotherapy for uveal melanomas at nice teaching hospital: 16 years' experience.
Caujolle JP; Mammar H; Chamorey E; Pinon F; Herault J; Gastaud P
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):98-103. PubMed ID: 19910136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
